GSA Capital Partners LLP lowered its stake in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 73.3% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 9,705 shares of the biopharmaceutical company’s stock after selling 26,623 shares during the quarter. GSA Capital Partners LLP’s holdings in Esperion Therapeutics were worth $449,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Aperio Group LLC purchased a new position in shares of Esperion Therapeutics during the second quarter valued at about $249,000. American International Group Inc. increased its position in shares of Esperion Therapeutics by 7.1% during the first quarter. American International Group Inc. now owns 8,814 shares of the biopharmaceutical company’s stock valued at $311,000 after buying an additional 584 shares during the period. State Board of Administration of Florida Retirement System purchased a new position in shares of Esperion Therapeutics during the first quarter valued at about $316,000. SG Americas Securities LLC increased its position in shares of Esperion Therapeutics by 74.5% during the second quarter. SG Americas Securities LLC now owns 7,008 shares of the biopharmaceutical company’s stock valued at $324,000 after buying an additional 2,991 shares during the period. Finally, Metropolitan Life Insurance Co. NY purchased a new position in shares of Esperion Therapeutics during the first quarter valued at about $385,000. Institutional investors own 83.30% of the company’s stock.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) opened at 55.54 on Friday. The stock has a 50 day moving average of $51.21 and a 200 day moving average of $43.08. The company’s market cap is $1.25 billion. Esperion Therapeutics, Inc. has a 52 week low of $9.40 and a 52 week high of $57.40.

Esperion Therapeutics (NASDAQ:ESPR) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.92) EPS for the quarter, missing analysts’ consensus estimates of ($1.67) by ($0.25). During the same quarter last year, the firm earned ($0.62) EPS. On average, analysts expect that Esperion Therapeutics, Inc. will post ($7.29) earnings per share for the current year.

Several equities analysts recently issued reports on the stock. UBS AG reiterated a “buy” rating and set a $57.00 price target (up previously from $52.00) on shares of Esperion Therapeutics in a research report on Tuesday, June 27th. Jefferies Group LLC upgraded shares of Esperion Therapeutics from a “hold” rating to a “buy” rating and cut their price objective for the stock from $85.00 to $55.00 in a report on Tuesday, August 8th. Stifel Nicolaus restated a “buy” rating and issued a $70.00 price objective (up previously from $60.00) on shares of Esperion Therapeutics in a report on Thursday, August 10th. Zacks Investment Research upgraded shares of Esperion Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, August 23rd. Finally, Needham & Company LLC upped their price objective on shares of Esperion Therapeutics from $58.00 to $72.00 and gave the stock a “positive” rating in a report on Tuesday, August 8th. Seven analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $55.35.

COPYRIGHT VIOLATION NOTICE: “Esperion Therapeutics, Inc. (ESPR) Shares Sold by GSA Capital Partners LLP” was originally posted by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2017/10/13/esperion-therapeutics-inc-espr-shares-sold-by-gsa-capital-partners-llp.html.

Esperion Therapeutics Profile

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Want to see what other hedge funds are holding ESPR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Esperion Therapeutics, Inc. (NASDAQ:ESPR).

Institutional Ownership by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.